News | Coronavirus (COVID-19) | May 19, 2020

Mayo Clinic Uses Artificial Intelligence to Help Assess Cardiac Danger From COVID-19

Mayo collaborates with AI vendor Ultromics to rapidly triage and quantify cardiac involvement in SARS-CoV-2 patients    

Mayo Clinic is using artificial intelligence EchoGo Core software from Ultromics to automatically analyize echocardiography images to assess the cardiac impact of COVID-19. The AI software is from Ultromics.

Mayo Clinic is using artificial intelligence EchoGo Core software from Ultromics to automatically analyize echocardiography images to assess the cardiac impact of COVID-19.

May 19, 2020 — A joint U.K.-U.S. research team is applying a pioneering artificial intelligence (AI) system to automatically analyze cardiac ultrasound imaging to map for the first time how the COVID-19 (SARS-CoV-2) virus attacks the heart with such deadly impact.

The coronavirus has been found to kill more than 1 in 10  victims with heart disease and also to significantly weaken the hearts of other sufferers.

This week, British health-tech company Ultromics and Mayo Clinic in the U.S. will use AI software, EchoGo Core, to analyze echocardiograms of COVID-19 victims, for clues about how the virus affects the human cardiovascular system.

Their findings will produce, for the first time, a map of the novel cardiac features of COVID-19 and help physicians rapidly triage and treat high-risk patients, potentially saving countless lives.

"To date, there is no way of linking the impact of the virus to predicted patient outcomes," Said Ultromics CEO Ross Upton. "By applying our technology to the evaluation of COVID associated echocardiograms, we can help understand the characteristics of cardiac involvement. We hope that by discovering a way to do this, patient management can be optimized – this is incredibly important where resources are scarce. Most importantly, we can give physicians the gift of time to treat those most in danger." 

Mayo Clinic is one of the world's leading centers of cardiology and its extensive cardiac knowledge will assist Ultromics in the development of an image analysis application to help clinicians in the fight against COVID-19. The collaboration will be led by Gary Woodward, CTO of Ultromics and Patricia A. Pellikka, M.D., cardiologist, and clinical researcher at Mayo Clinic.

The COVID-19 coronavirus has considerable potential for cardiovascular impact including COVID induced microvascular disease and myocarditis, and side-effects from some treatments, known as therapy-associated cardiotoxicity.

The multi-site study will look at 500 COVID-19 positive men and women, aged between 18 and 89. These participants will have undergone a clinically indicated echocardiography exam during a three-month period. The primary objective is the assessment of automated cardiac measurements, ejection fraction and global longitudinal strain, for the classification of COVID-19 patient outcomes.

EchoGo Core can provide physicians with an alternative streamlined solution for monitoring and identifying heart disease, enabling healthcare providers, no matter what experience level, to perform analysis with ease. This could be hugely important in giving physicians freed time to provide high quality, patient-centric care.

Echocardiograms have a proven role in the identification and assessment of virtually all cardiac disease entities. The non-invasive method is cost-effective and widely available, ideal for bedside assessment of patients with suspected cardiac complications of COVID-19.

What Does the EchoGo Core AI Software Do?

EchoGo Core applies artificial intelligence to automate the analysis on echocardiograms. The system has been validated with the National Health Service (NHS) in the U.K., in one of the largest echo studies of its kind, with over 8,000 patients in over 30 sites. It is a fully automated, zero-click system which has zero variability, so it allows physicians, regardless of skill level, to make an efficient and accurate diagnosis.

Ultromics applies artificial intelligence to develop echo-based tools in cardiovascular imaging, by combining deep clinical insight with machine learning and some of the largest echo datasets in the world. The revolutionary platform assists clinicians in their decision-making, without disrupting clinical workflow, to drive diagnostic quality and patient care.    

EchoGo Core is FDA-cleared for use in the United States, not CE marked for use in the European Union.

For more information: www.ultromics.com

 

Related Artificial intelligence Application in Echo and Cardiology:

Global Longitudinal Strain Echo and AI Can Aid Fight Against Heart Failure

New Cardiac Diagnostic Tool Helps Automate Point-of-Care Ultrasound Screening

Mayo Clinic Uses Artificial Intelligence to Help Assess Cardiac Danger From COVID-19

Northwestern Medicine Introduces Artificial Intelligence to Improve Ultrasound Imaging

FDA Clears Ultromics Echocardiography AI for Automated Identification of Coronary Artery Disease

 

TomTec Releases New Echocardiography Technologies With AI and Auto Quantification

VIDEO: AI-Assisted Automatic Ejection Fraction for Point-of-Care Ultrasound

New Cardiac Diagnostic Tool Helps Automate Point-of-Care Ultrasound Screening

FDA Clears Caption Health AI-assisted Point-of-care Ejection Fraction Evaluation

WEBINAR: Intelligently Efficient Adult Echo Structured Reporting

 

JAMA Cardiology Article Shows Effectiveness of AI-Guided Ultrasound Software 

What is New in Cardiology? A Review of All Major Emerging Technologies for Heart Diseases

Expanded AI-based Echocardiography Analysis and Reporting Added to Konica Minolta Exa Cardio PACS 

FDA Clears First AI-Powered Algorithm Suite for Personal ECG Monitoring

More Than 50,000 Children Screened for Congenital Heart Defects Using AI-enabled Stethoscopes

Related Content

Cloud AI software-as-a-service (SaaS) can help streamline workflows and increase throughput, enabling echocardiographers to better measure global longitudinal strain (GLS) more routinely without impacting productivity. This is an example of the Ultromics EchoGo Core artificial intelligence algorithm with fully automates GLS.

Cloud artificial intelligence (AI) software-as-a-service (SaaS) can help streamline workflows and increase throughput, enabling echocardiographers to better measure global longitudinal strain (GLS) more routinely without impacting productivity. This is an example of the Ultromics EchoGo Core artificial intelligence algorithm, which fully automates GLS. Learn more at www.ultromics.com.

Feature | Artificial Intelligence | March 16, 2021
Heart failure (HF) is a prevalent ye
Ultromics will offer EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

News | Artificial Intelligence | January 06, 2021
January 6, 2021 — The U.S.
An example of a body composition analysis of an abdominal CT slice with the subcutaneous fat in green, skeletal muscle red and visceral fat in yellow. This was automatically identified and analyzed via a deep learning algorithm to assess the risk for heart attack and stroke in more than 12,000 patients. #RSNA2020 #RSNA20 #RSNA

An example of a body composition analysis of an abdominal CT slice with the subcutaneous fat in green, skeletal muscle red and visceral fat in yellow. This was automatically identified and analyzed via a deep learning algorithm to assess the risk for heart attack and stroke in more than 12,000 patients.

Feature | Artificial Intelligence | December 02, 2020
December 2, 2020 – Automated deep learning analysis of abdominal...
The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

News | Artificial Intelligence | November 24, 2020
November 24, 2020 — The U.S.
Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS.

Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS. 

News | Artificial Intelligence | November 12, 2020
November 12, 2020 – Konica Minolta Healthcare Americas Inc. and DiA Imaging Analysis Ltd.
The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

Feature | Artificial Intelligence | September 29, 2020 | Joe Fornadel, J.D., and Wes Moran, J.D.
The number of Federal Drug Administration (FDA)-approved AI-based algorithms is significant and has grown at a steady
Selfied might be used with AI to identify patients with heart disease. Getty Images

Getty Images

News | Artificial Intelligence | August 24, 2020
August 24, 2020 — Sending a photo selfie to the doctor could be a cheap and simple way of detecting heart disease usi
aption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

Caption Health a leader in medical AI technology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an updated version of Caption Interpretation, which uses artificial intelligence (AI) to enable clinicians to obtain quick, easy and accurate measurements of cardiac ejection fraction (EF) at the point of care.

News | Artificial Intelligence | August 19, 2020
August 19, 2020 — Caption Health a leader in medical AI technology, has received U.S.